

---

# Rare Pediatric Disease Priority Review Vouchers Guidance for Industry

## ***DRAFT GUIDANCE***

**This guidance document is being distributed for comment purposes only.**

Comments and suggestions regarding this draft document should be submitted within 60 days of publication in the *Federal Register* of the notice announcing the availability of the draft guidance. Submit electronic comments to <https://www.regulations.gov>. Submit written comments to the Dockets Management Staff (HFA-305), Food and Drug Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852. All comments should be identified with the docket number listed in the notice of availability that publishes in the *Federal Register*.

For questions regarding this draft document, contact (OOPD) Aaron Friedman at 301-796-2989, or (CBER) Stephen Ripley at 240-402-7911, or (CDER) Althea Cuff at 301-796-4061, or (OPT) Terrie Crescenzi at 301-796-8646.

**U.S. Department of Health and Human Services  
Food and Drug Administration  
Center for Biologics Evaluation and Research (CBER)  
Center for Drug Evaluation and Research (CDER)  
Office of Orphan Products Development (OOPD)  
Office of Pediatric Therapeutics (OPT)**

**July 2019**

**Revision 1**

# Rare Pediatric Disease Priority Review Vouchers Guidance for Industry

Additional copies are available from:

Office of Communications, Division of Drug Information  
Center for Drug Evaluation and Research  
Food and Drug Administration  
10903 New Hampshire Ave., Bldg. 51, rm. 2201  
Silver Spring, MD 20993-0002

Tel: 301-796-3400; Fax: 301-847-8714; E-mail: [druginfo@fda.hhs.gov](mailto:druginfo@fda.hhs.gov)

<http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/default.htm>

or

Office of Communication, Outreach, and Development  
Center for Biologics Evaluation and Research  
Food and Drug Administration  
10903 New Hampshire Ave., Bldg. 71, rm. 3128  
Silver Spring, MD 20993-0002

Tel: 800-835-4709 or 240-402-8010; E-mail: [ocod@fda.hhs.gov](mailto:ocod@fda.hhs.gov)

<http://www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/default.htm>

or

Office of Orphan Products Development  
Office of the Commissioner  
Food and Drug Administration  
10903 New Hampshire Ave., Bldg. 32, rm. 5295  
Silver Spring, MD, 20993

Tel: 301-796-8660; E-mail: [orphan@fda.hhs.gov](mailto:orphan@fda.hhs.gov)

<http://www.fda.gov/orphan>

or

Office of Pediatric Therapeutics  
Office of the Commissioner  
Food and Drug Administration  
10903 New Hampshire Ave., Bldg. 32  
Silver Spring, MD, 20993

Tel: 301-796-8659; E-mail: [OPT@fda.hhs.gov](mailto:OPT@fda.hhs.gov)

<https://www.fda.gov/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/OfficeofScienceandHealthCoordination/ucm2018186.htm>

**U.S. Department of Health and Human Services  
Food and Drug Administration  
Center for Biologics Evaluation and Research (CBER)  
Center for Drug Evaluation and Research (CDER)  
Office of Orphan Products Development (OOPD)  
Office of Pediatric Therapeutics (OPT)**

**July 2019**

**Revision 1**

## TABLE OF CONTENTS

<b>I.</b>	<b>INTRODUCTION.....</b>	<b>1</b>
<b>II.</b>	<b>BACKGROUND AND OVERVIEW .....</b>	<b>1</b>
<b>III.</b>	<b>DEFINITIONS, POLICIES, AND PROCEDURES — QUESTIONS AND ANSWERS .....</b>	<b>3</b>
<b>A.</b>	<b>Rare Pediatric Disease Product Applications.....</b>	<b>3</b>
<b>B.</b>	<b>Requesting Rare Pediatric Disease Designation.....</b>	<b>10</b>
<b>C.</b>	<b>Requesting a Rare Pediatric Disease Priority Review Voucher.....</b>	<b>16</b>
<b>D.</b>	<b>Using and Transferring a Rare Pediatric Disease Priority Review Voucher.....</b>	<b>18</b>
<b>E.</b>	<b>Specific Eligibility Questions.....</b>	<b>20</b>
<b>F.</b>	<b>Relationship between Rare Pediatric Disease Designation and Orphan-Drug Designation.....</b>	<b>22</b>
<b>G.</b>	<b>Agency's Responsibilities and Roles.....</b>	<b>23</b>

*Contains Nonbinding Recommendations*

*Draft – Not for Implementation*

1 **Rare Pediatric Disease Priority Review Vouchers,**  
2 **Draft Guidance for Industry**  
3

4 This draft guidance, when finalized, will represent the current thinking of the Food and Drug  
5 Administration (FDA or Agency) on this topic. It does not establish any rights for any person and is not  
6 binding on FDA or the public. You can use an alternative approach if it satisfies the requirements of the  
7 applicable statutes and regulations. To discuss an alternative approach, contact the FDA staff responsible  
8 for this guidance as listed on the title page.

9  
10  
11 **I. INTRODUCTION**  
12

13 This guidance provides information on the implementation of section 908 of the Food and Drug  
14 Administration Safety and Innovation Act (FDASIA),<sup>1</sup> which added section 529 to the Federal  
15 Food, Drug, and Cosmetic Act (the FD&C Act).<sup>2</sup> Under section 529, FDA<sup>3</sup> will award priority  
16 review vouchers to sponsors of certain rare pediatric disease product applications that meet the  
17 criteria specified in that section.  
18

19 In general, FDA’s guidance documents do not establish legally enforceable responsibilities.  
20 Instead, guidances describe the Agency’s current thinking on a topic and should be viewed only  
21 as recommendations, unless specific regulatory or statutory requirements are cited. The use of  
22 the word *should* in Agency guidances means that something is suggested or recommended, but  
23 not required.  
24

25 **II. BACKGROUND AND OVERVIEW**  
26

27 Section 529 of the FD&C Act is intended to encourage development of new drug and biological  
28 products (“drugs”) for the prevention and treatment of certain rare pediatric diseases.<sup>4</sup> Although  
29 there are existing incentive programs to encourage the development and study of drugs for rare  
30 diseases, pediatric populations, and unmet medical needs, section 529 provides an additional  
31 incentive for rare pediatric diseases, which may be used alone or in combination with other  
32 incentive programs. These other incentive programs include: orphan-drug designation and the  
33 associated benefits under the Orphan Drug Act for rare disease therapies;<sup>5</sup> programs that  
34 encourage or require the study of drugs used in pediatric populations under the Best

---

<sup>1</sup> Public Law 112-144, enacted July 9, 2012.

<sup>2</sup> 21 U.S.C. 360ff. Unless otherwise noted, references to “sections” in this guidance are to sections of the FD&C Act.

<sup>3</sup> Throughout this document, we use the terms “we” and “FDA” interchangeably.

<sup>4</sup> For the purposes of this guidance, references to drugs and drug and biological products include drugs approved under section 505 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355) and biological drug products licensed under section 351 of the Public Health Service Act (42 U.S.C. 262).

<sup>5</sup> Public Law 97-414, as amended, codified at sections 526-528 of the FD&C Act (21 U.S.C. 360aa-360ee).

## *Contains Nonbinding Recommendations*

*Draft – Not for Implementation*

35 Pharmaceuticals for Children Act (BPCA) and the Pediatric Research Equity Act (PREA);<sup>6</sup> and  
36 various programs to facilitate and expedite development and review of new drugs to address  
37 unmet medical needs in the treatment of serious or life-threatening conditions.<sup>7</sup> Even so,  
38 Congress has recognized that there remain unmet medical needs among patients with rare  
39 diseases that occur primarily in pediatric populations. By enacting section 529, Congress  
40 intended to stimulate new drug development for rare pediatric diseases by offering additional  
41 incentives for obtaining FDA approval of these products.

42  
43 Under section 529, the sponsor of a human drug application (as defined in section 735(1) of the  
44 FD&C Act<sup>8</sup>) for a rare pediatric disease drug may be eligible for a voucher that can be used to  
45 obtain a priority review for a subsequent human drug application submitted under section  
46 505(b)(1) of the FD&C Act<sup>9</sup> or section 351 of the Public Health Service (PHS) Act after the date  
47 of approval of the rare pediatric disease drug.

48  
49 On September 30, 2016, the Advancing Hope Act of 2016 updated the definition of “rare  
50 pediatric disease” (see Question 1) and created a requirement for sponsors seeking a rare  
51 pediatric disease priority review voucher to request the voucher upon submission of the rare  
52 pediatric disease product application (see Question 14). In addition, the Advancing Hope Act

---

<sup>6</sup> See, e.g., Public Law 107-109 (January 4, 2002) and Public Law 108-155 (December 3, 2003), codified in sections 505A and 505B of the FD&C Act (21 U.S.C. 355a-355c).

<sup>7</sup> These programs include, among others, fast track designation, breakthrough therapy designation, accelerated approval, priority review designation, regenerative medicine advanced therapy designation, and programs for certain tropical disease products and antibiotics. For more information, you may refer to the FDA Guidance, Expedited Programs for Serious Conditions – Drugs and Biologics, *available at* <http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM358301.pdf>; FDA Guidance, Expedited Programs for Regenerative Medicine Therapies for Serious Conditions, *available at* <https://www.fda.gov/downloads/biologicsbloodvaccines/guidancecomplianceregulatoryinformation/guidances/cellul arandgenetherapy/ucm585414.pdf>, FDA Draft Guidance, Neglected Tropical Diseases of the Developing World: Developing Drugs for Treatment or Prevention, *available at* <http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM269221.pdf>; FDA Draft Guidance, Tropical Disease Priority Review Vouchers, *available at* <http://www.fda.gov/downloads/Drugs/Guidances/UCM080599.pdf>; and Food and Drug Administration Innovation and Safety Act (FDASIA), Public Law 112-144, Title VIII—Generating Antibiotic Incentives Now.

<sup>8</sup> The statutory definition for the term “human drug application” is “an application for--

(A) approval of a new drug submitted under section 355(b) of this title, or

(B) licensure of a biological product under subsection (a) of section 262 of Title 42.

Such term does not include a supplement to such an application, does not include an application with respect to whole blood or a blood component for transfusion, does not include an application with respect to a bovine blood product for topical application licensed before September 1, 1992, an allergenic extract product, or an in vitro diagnostic biologic product licensed under section 262 of Title 42, does not include an application with respect to a large volume parenteral drug product approved before September 1, 1992, does not include an application for a licensure of a biological product for further manufacturing use only, and does not include an application or supplement submitted by a State or Federal Government entity for a drug that is not distributed commercially. Such term does include an application for licensure, as described in subparagraph (B), of a large volume biological product intended for single dose injection for intravenous use or infusion.”

Section 735(1) of the FD&C Act (21 U.S.C. 379g(1)). The definition does not cover applications for medical devices.

<sup>9</sup> Because 505(b)(2) new drug applications (NDAs) are submitted under section 505(b)(1), all references to NDAs submitted under section 505(b)(1) include 505(b)(2) applications.

## *Contains Nonbinding Recommendations*

*Draft – Not for Implementation*

53 clarified that no sponsor of a rare pediatric disease product application may receive more than  
54 one priority review voucher issued under any section of the FD&C Act for the same drug. On  
55 December 13, 2016, the 21st Century Cures Act extended the rare pediatric disease priority  
56 review voucher program as follows:

57  
58 [FDA] may not award any [rare pediatric disease] priority review vouchers...after  
59 September 30, 2020, unless the rare pediatric disease product application (A) is for a drug  
60 that, not later than September 30, 2020, is designated...as a drug for a rare pediatric  
61 disease; and (B) is, not later than September 30, 2022, approved under section 505(b)(1)  
62 of [the FD&C Act] or section 351 of the [PHS Act].<sup>10</sup>  
63

64 Therefore, under the sunset provisions as applicable at the time of issuance of this draft  
65 guidance, after September 30, 2020, FDA may only award a voucher if the drug has rare  
66 pediatric disease designation, and that designation was granted by September 30, 2020. After  
67 September 30, 2022, FDA may not award any rare pediatric disease priority review vouchers.  
68

69 This guidance revises the draft guidance of the same title issued in November 2014 to reflect  
70 these updates. This guidance is intended to assist developers of rare pediatric disease products in  
71 assessing whether their product may be eligible for rare pediatric disease designation and a rare  
72 pediatric disease priority review voucher. It also clarifies the process for requesting such  
73 designations and vouchers, sponsor responsibilities upon approval of a rare pediatric disease  
74 product application, and the parameters for using and transferring a rare pediatric disease priority  
75 review voucher.  
76

### 77 **III. DEFINITIONS, POLICIES, AND PROCEDURES — QUESTIONS AND** 78 **ANSWERS**

#### 79 80 **A. Rare Pediatric Disease Product Applications** 81

#### 82 **Q1. What is a “rare pediatric disease”?** 83

84 Section 529(a)(3) defines a “*rare pediatric disease*” as a disease that meets each of the following  
85 criteria:  
86

- 87 (A) The disease is a serious or life-threatening disease in which the serious or life-  
88 threatening manifestations primarily affect individuals aged from birth to 18 years,  
89 including age groups often called neonates, infants, children, and adolescents [; ***and***]  
90 (B) The disease is a rare disease or condition, within the meaning of section 526 [of the  
91 FD&C Act].  
92

93 *Serious or life-threatening manifestations primarily affect children*

---

<sup>10</sup> Section 529(b)(5). Congress may consider whether to extend these time restrictions in the future, so interested persons should consult current law with respect to these restrictions.

## *Contains Nonbinding Recommendations*

*Draft – Not for Implementation*

94 Of note, section 529 describes the pediatric population as from birth through 18 years.<sup>11</sup> This  
95 age range differs from how FDA defines the pediatric population in other contexts. Generally,  
96 for drug and biological products, FDA considers the pediatric population to include patients from  
97 birth through 16 years.<sup>12</sup> This guidance uses the term “children” to mean the definition of the  
98 pediatric population in section 529: individuals aged from birth to 18 years.

99  
100 FDA interprets the current definition of “rare pediatric disease” and its reference to “serious or  
101 life-threatening manifestations of the disease or condition” using the following principles:

- 102 • A manifestation of the disease or condition should be serious or life-threatening in  
103 children aged 0 through 18 years of age. Manifestations include expressions and  
104 symptoms of the disease or condition. Note that “manifestations” does not mean the  
105 onset of the disease or condition or the onset of treatment. For example, if a disease or  
106 condition’s onset typically begins in childhood, but manifestations of the disease or  
107 condition do not become serious or life-threatening until adulthood, the disease or  
108 condition is not a rare pediatric disease. Similarly, if treatment for the disease or  
109 condition begins in childhood, but under current standard of care the manifestations of  
110 the disease or condition are not serious or life-threatening in children, the disease or  
111 condition is not a rare pediatric disease.
- 112 • FDA will consider the manifestations of the disease or condition in the context of  
113 standard of care for the disease or condition. Specifically, FDA will consider what  
114 manifestations of the disease or condition are serious or life-threatening in children under  
115 standard treatment for the disease or condition. Therefore, FDA will not consider the  
116 serious or life-threatening manifestations of the disease or condition that only occur when  
117 the disease is left untreated if that is not the standard of care.
- 118 • FDA will assess the serious or life-threatening manifestations of the disease or condition  
119 and determine which manifestations primarily affect children and which primarily affect  
120 adults. Factors in determining if a manifestation primarily affects children include:  
121 timing and rate of disease progression (e.g., end-stage organ disease occurs in childhood),  
122 manifestations of abnormal growth or development, and whether the proportion of  
123 children is greater than the proportion of adults with the given manifestation. If the  
124 disease or condition has a manifestation that primarily affects children, FDA will  
125 consider the disease or condition to be a rare pediatric disease.<sup>13</sup>
- 126 • The serious and life-threatening manifestations of the disease or condition that primarily  
127 affect children will also be a factor in determining whether the application qualifies for a  
128 voucher (see Questions 3 and 4).

---

<sup>11</sup> We interpret “from birth to 18 years” as including all individuals less than 19 years of age (i.e., as from 0 through 18 years). Similarly, FDA interprets 21 CFR 201.57(c)(9)(iv), which describes a pediatric age range as “from birth to 16 years,” as including all individuals less than 17 years of age (i.e., as from 0 through 16 years).

<sup>12</sup> See 21 CFR 201.57(c)(9)(iv).

<sup>13</sup> That is not to say that manifestations that primarily affect adults cannot also be serious or life-threatening in children. But based on the statutory definition, FDA is required to determine which manifestations primarily affect children and which primarily affect adults. For example, FDA has determined that impaired lung function is a serious or life-threatening manifestation of cystic fibrosis that primarily affects adults, but can also be serious or life-threatening in children. FDA considers cystic fibrosis to be a rare pediatric disease based on other manifestations of the disease that do primarily affect children.

## *Contains Nonbinding Recommendations*

*Draft – Not for Implementation*

129  
130  
131  
132  
133  
134  
135  
136  
137  
138  
139  
140  
141  
142  
143  
144  
145  
146  
147  
148  
149  
150  
151  
152  
153  
154  
155  
156  
157  
158  
159  
160  
161

### *Rare disease or condition*

Section 526 of the FD&C Act defines a “rare disease or condition” as any disease or condition that affects (1) less than 200,000 persons in the United States (U.S.) or (2) affects more than 200,000 in the U.S. and for which there is no reasonable expectation that the cost of developing and making available in the U.S. a drug for such disease or condition will be recovered from sales in the U.S. of such drug.

A drug may also meet the “rare disease or condition” requirement if it is for an “orphan subset” of a disease or condition that otherwise affects 200,000 or more persons in the U.S.<sup>14</sup> In order for such drug to qualify as a drug for a “rare pediatric disease,” the orphan subset must be serious or life-threatening and the serious or life-threatening manifestations of the orphan subset must primarily affect individuals aged from birth to 18 years.<sup>15</sup>

The calculation of prevalence estimates will depend on whether the drug is a therapeutic drug or a vaccine, diagnostic drug,<sup>16</sup> or preventive drug, as follows:

- *For therapeutic drugs*, prevalence estimates of the entire affected U.S. population should be based on the number of individuals diagnosed with the disease or condition. For some diseases and conditions, individuals may have an underlying genetic abnormality at birth but may not develop manifestations of the disease until later, if ever. In these instances, whether individuals are considered “diagnosed” for the purpose of estimating prevalence may depend on whether the product is intended to treat an underlying genetic abnormality, attenuate or prevent progression of the clinical expression of the disease, or treat the clinical symptoms or manifestations of the disease.
- *For vaccines, diagnostic drugs, and preventive drugs*, prevalence estimates should be based on the number of persons of all ages to whom the drug will be administered in the U.S. annually.

For information on how to document prevalence in designation requests, see the responses to Questions 9 and 15.

---

<sup>14</sup> An “orphan subset” requires demonstration that use of the drug outside of the subset of interest (in the remaining persons with the disease or condition) would not be appropriate owing to one or more properties of the drug, such as drug toxicity, mechanism of action, or previous clinical experience with the drug. *See* 21 CFR 316.3(b)(13); 21 CFR 316.20(b)(6).

<sup>15</sup> *See* Section 529(a)(3)(A).

<sup>16</sup> An application may qualify as a rare pediatric disease product application if it is for a drug or biologic that is a diagnostic for the management of a disease or condition. We note, however, that such diagnostic products must be the subject of a NDA or BLA to qualify as a rare pediatric disease product application, as diagnostic products that are the subject of medical device applications are not eligible for a rare pediatric diseases priority review voucher. An application for a drug for the initial diagnosis of a disease or condition will not qualify as a rare pediatric disease product application.



## Contains Nonbinding Recommendations

Draft – Not for Implementation

162 Qualifying as a drug for a “rare pediatric disease” is not sufficient to receive a priority review  
163 voucher. For sponsors to receive such a voucher, the application for the drug must meet all of  
164 the remaining eligibility criteria described in response to Question 2.<sup>17</sup>

165

### 166 **Q2. What is a “rare pediatric disease product application”?**

167

168 The term *rare pediatric disease product application* is defined in section 529(a)(4) of the FD&C  
169 Act. It refers to an application that:

170

- 171 • Is a human drug application as defined in section 735(1) of the FD&C Act<sup>18</sup>:
  - 172 – For prevention or treatment<sup>19</sup> of a *rare pediatric disease* (see Questions 1 and 3);
  - 173 – That contains no active ingredient (including any ester or salt of the active ingredient)
  - 174 that has been previously approved in any other application under section 505(b)(1),
  - 175 505(b)(2), or 505(j) of the FD&C Act or section 351(a) or 351(k) of the PHS Act.
  - 176
  - 177
- 178 • That FDA deems eligible for priority review.<sup>20</sup>
- 179
- 180 • Is submitted under section 505(b)(1) of the FD&C Act<sup>21</sup> or section 351(a) of the Public  
181 Health Service Act.
- 182
- 183 • Relies on clinical data derived from studies examining a pediatric population and dosages  
184 of the drug intended for that population (see Question 4).
- 185
- 186 • Does not seek approval for an adult indication in the original rare pediatric disease  
187 product application (see Question 5); and
- 188
- 189 • Is approved after the date of enactment of the Advancing Hope Act of 2016 (September  
190 30, 2016).<sup>22</sup>
- 191

---

<sup>17</sup> See section 529(a)(4).

<sup>18</sup> See footnote 8.

<sup>19</sup> See footnote 15.

<sup>20</sup> Certain applications may receive priority review pursuant to a statutory mandate (i.e., sections 524A and 505A of the FD&C Act). However, in determining whether an application qualifies for priority review within the meaning of this provision (i.e., section 529(a)(4)(C) of the FD&C Act), if a rare pediatric disease priority review voucher is requested, the Agency will determine whether the application satisfies the criteria for eligibility for a priority review designation, i.e., whether the drug treats a serious condition and, if approved, would provide a significant improvement in safety or effectiveness. For more information on the priority review designation see footnote 7, referring to FDA’s guidance Expedited Programs for Serious Conditions—Drugs and Biologics (May 2014).

<sup>21</sup> See footnote 9.

<sup>22</sup> Note that there are limitations on when rare pediatric disease priority review vouchers can be awarded: FDA may not award a voucher if the application was submitted to FDA prior to October 7, 2012 (i.e., 90 days after enactment of the Prescription Drug User Fee Amendments (PDUFA) of 2012), section 529(b)(3); and see Section II of this guidance for a description of the sunset provision for awarding vouchers under the law as applicable at the time of issuance of this draft guidance.

*Contains Nonbinding Recommendations*

*Draft – Not for Implementation*

192  
193  
194  
195  
196  
197  
198  
199  
200  
201  
202  
203  
204  
205  
206  
207  
208  
209  
210  
211  
212  
213  
214  
215  
216  
217  
218  
219  
220  
221  
222  
223  
224  
225  
226  
227  
228  
229  
230  
231  
232  
233  
234

**Q3. What does it mean to be “for” prevention or treatment of a rare pediatric disease?<sup>23</sup>**

To be eligible for a voucher, the drug should be (1) approved for a rare pediatric disease and (2) treat or prevent a serious or life-threatening manifestation of the disease or condition that affects children. These serious or life-threatening manifestations may be the manifestations that primarily affect children, but they are not required to be, so long as the approved indication is clinically meaningful to pediatric patients with the disease or condition. For example:

- A drug may meet this standard if the approved indication is explicitly for treatment or prevention of a serious or life-threatening manifestation of the disease or condition that affects children.
- A drug may also meet this standard if the drug treats or prevents the underlying cause of the disease or condition and the approved indication is for treatment or prevention of the disease or condition generally.

The intent of the statute is to award a voucher for a drug that benefits the pediatric patients with the rare pediatric disease or condition. FDA will look at the totality of the evidence to determine if the approval is clinically meaningful for the serious or life-threatening manifestations of the disease that affect children.

FDA encourages sponsors to work with the relevant review division or office in CBER or CDER to ensure they are studying the drug in a way that establishes safety and efficacy for the drug “for” a rare pediatric disease. The priority review voucher request should include scientific justification of how the approved indication will be clinically meaningful to pediatric patients with the disease or condition. We expect a written description of the data and endpoints from the submitted studies that supports a determination that the drug is for pediatric patients with the rare pediatric disease as described above.

**Q4. What does “relies on clinical data derived from studies examining a pediatric population and dosages of the drug intended for that population” mean?**

We interpret “relies on clinical data derived from studies examining a pediatric population and dosages of the drug intended for that population” to mean that, to be eligible for a voucher, the approved product:

- should have been studied in a clinically meaningful pediatric population with the rare disease (although the studies may also include adults in appropriate circumstances), and
- the pediatric data should have been critical to obtaining adequate labeling for the pediatric population in terms of safety, effectiveness, and dosage information (although data from studies including adults may also have supported the pediatric labeling in appropriate circumstances).

---

<sup>23</sup> See Section 529(a)(4)(A)(i).

## *Contains Nonbinding Recommendations*

*Draft – Not for Implementation*

235 It is important that applicants seeking a voucher submit data adequate for labeling the drug for  
236 use by the full range of affected pediatric patients, within reasonable limits (i.e., all pediatric  
237 patient age ranges affected by the disease that are reasonable to include in the studies without  
238 undue delays in completing the studies and submitting the application). The studied pediatric  
239 population should be clinically meaningful and represent more than a token pediatric population.  
240 Such labeling aligns with the intent of section 529, which is to help address the unmet medical  
241 needs of pediatric patients with rare pediatric diseases.

242

243 Note that sponsors are not required to study a manifestation of the disease or condition that  
244 primarily affects pediatric patients, but the studies should support approval for a rare pediatric  
245 disease in a way that is clinically meaningful to pediatric patients with the disease or condition  
246 (see Question 3).

247

### 248 **Q5. What does “Does not seek approval for an adult indication in the original rare** 249 **pediatric disease product application” mean?**

250

251 An applicant cannot receive a rare pediatric disease priority review voucher if the application  
252 seeks approval for an adult indication in the original rare pediatric disease product application.  
253 We interpret this criterion to mean that, to preserve voucher eligibility, the applicant cannot seek  
254 approval for a *different* adult indication (i.e., for a different disease/condition) in the original rare  
255 pediatric disease application. If the applicant seeks approval for use by pediatric and adult  
256 populations with the rare pediatric disease, the applicant will still be eligible for a voucher if the  
257 approved use includes pediatric use, as described in Questions 3 and 4. If the applicant obtains  
258 approval for use *only* in an adult population with the rare pediatric disease, the applicant is  
259 ineligible for a voucher.

260

261 Thus, under this interpretation, an applicant can preserve voucher eligibility even if the applicant  
262 seeks approval for use by adults in addition to pediatric patients with the rare pediatric disease.  
263 One reason we are interpreting the statute in this way is to avoid incentivizing sponsors to  
264 exclude adults affected by the rare pediatric disease from clinical trials or to exclude adult data  
265 from the subsequent marketing application solely for the sake of voucher eligibility, when such  
266 exclusions may not be scientifically or ethically acceptable for the reasons described below.

267

268 *Clinical Trial Design – Clinical Trials for a Potential Rare Pediatric Disease Product May Need*  
269 *to Include Individuals Over 18 Years of Age for Scientific or Ethical Reasons:* Clinical trials for  
270 rare diseases and conditions are challenging because, among other factors, the small patient  
271 populations limit the opportunities for study and verification of results. Because such clinical  
272 trials are likely to be small and at risk of being underpowered, FDA expects that rare disease  
273 clinical development programs will attempt to include all patients with the rare disease or  
274 condition that are available for study and who could reasonably be expected to benefit from the  
275 intervention, regardless of the age of the patient (where feasible and appropriate based on the  
276 disease/condition and expected effects of intervention).<sup>24</sup> Indeed, studies using novel therapies  
277 should generally be conducted in young adults (18 to 21 years of age) prior to exposing

---

<sup>24</sup> See, e.g., ICH and FDA Guidance, “E11 Clinical Investigation of Medicinal Products in the Pediatric Population,” Section II.A, available at <http://www.fda.gov/downloads/RegulatoryInformation/Guidances/ucm129477.pdf>.

## ***Contains Nonbinding Recommendations***

*Draft – Not for Implementation*

278 adolescents and younger pediatric patients; for children to be included in early phase  
279 investigations, there must be a prospect of direct benefit for an individual child to be studied in a  
280 clinical trial in which more than a minor increase over minimal risk is presented by an  
281 intervention or procedure.<sup>25</sup> For all of these reasons, it may not be scientifically or ethically  
282 appropriate to exclude those over 18 years of age from a clinical trial evaluating a potential rare  
283 pediatric disease product.

284

285 *Data to Include in a Marketing Application – Available Adult Safety and Effectiveness Data*  
286 *Must be Included in the Application:* If clinical safety and effectiveness data are available in an  
287 adult population (i.e., individuals over 18 years) at the time of the submission of an original  
288 application for a potential rare pediatric disease product, these data must be included in the  
289 application for FDA’s review.<sup>26</sup> In many cases, if there is a population over 18 years of age with  
290 the rare pediatric disease that could benefit from the product and for whom there are available  
291 data to support the evaluation of the safety and effectiveness of the product, labeling for such a  
292 population should be sought in the original product application.

293

294 As noted, seeking approval for use in both adults and pediatric patients with the rare pediatric  
295 disease will not affect voucher eligibility. However, we remind applicants seeking a voucher  
296 that – whether or not they seek approval for use in an adult population – we expect them to  
297 submit data adequate for labeling the drug for use by the full range of affected pediatric patients  
298 (see response to Question 4).

299

300 Note that after a sponsor has been awarded a rare pediatric disease priority review voucher for  
301 approval of a drug, the sponsor can develop the same drug for additional indications, including a  
302 different adult indication, without losing the voucher.

303

### **Q6. What user fees apply to a rare pediatric disease product application?**

304

305  
306 User fees for human drug applications are described in section 736 of the FD&C Act.<sup>27</sup> In  
307 general, a rare pediatric disease product application is subject to these statutory requirements like  
308 any other application. Such applications may, however, be eligible for exemptions from some  
309 fees if they have received orphan-drug designation. See FDA’s Guidance for Industry User Fee  
310 Waivers, Reductions, and Refunds for Drug and Biological Products.<sup>28</sup>

311

312 User fees also apply to applications for which a rare pediatric disease priority review voucher is  
313 used, as described in Question 22.

314

### **Q7. What are the sponsor’s responsibilities after approval of a rare pediatric disease product application?**

315

316

317

---

<sup>25</sup> 21 CFR 50.52 and 50.53; *see also* ICH and FDA Guidance, “E11 Clinical Investigation of Medicinal Products in the Pediatric Population,” footnote 19, Section II.C.

<sup>26</sup> 21 CFR 314.50(d)(5)(iv); 21 CFR 601.2; 21 U.S.C. 379h.

<sup>27</sup> 21 U.S.C. 379h.

<sup>28</sup> Available at

<http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm079298.pdf>.

## *Contains Nonbinding Recommendations*

*Draft – Not for Implementation*

318 The sponsor of an approved rare pediatric disease product application must submit a report to  
319 FDA no later than 5 years after approval that addresses, for each of the first 4 post-approval  
320 years:

- 321 • the estimated population in the U.S. with the rare pediatric disease for which the  
322 product was approved (both the entire population and the population aged 0 through  
323 18 years),
- 324 • the estimated demand in the U.S. for the product, and
- 325 • the actual amount of product distributed in the U.S.<sup>29</sup>

326  
327 Sponsors should submit such reports to the review division or office within CDER or CBER that  
328 reviewed the new drug application (NDA)/ biologics license application (BLA) for the rare  
329 pediatric disease product. This report should be prominently marked, “Rare Pediatric Disease  
330 Product Post-Approval Report.”

331

### **B. Requesting Rare Pediatric Disease Designation**

332

#### **Q8. What is the rare pediatric disease designation process?**

333

334 Under section 529(d), a sponsor may choose to request rare pediatric disease designation. FDA  
335 strongly recommends that sponsors planning to request a voucher request rare pediatric disease  
336 designation. Under the law as applicable at the time of issuance of this draft guidance, FDA may  
337 not award any vouchers after September 30, 2020, unless the application is for a drug that was  
338 designated as a drug for a rare pediatric disease by September 30, 2020.<sup>30</sup>

339

340  
341 If a sponsor chooses to request such designation, section 529(d)(2) provides that it shall do so “at  
342 the same time” that they submit a request for orphan-drug designation under section 526<sup>31</sup> or a  
343 request for fast track designation under section 506.<sup>32</sup> FDA will recognize a request for rare  
344 pediatric disease designation to be submitted “at the same time” as a request for orphan-drug  
345 designation or fast track designation if the requests are received by FDA within two weeks of  
346 each other.

347

348  
349 Note that, while a request for rare pediatric disease designation may be submitted at the same  
350 time as a request for orphan-drug designation or fast track designation, each request should be  
351 submitted as a separate proposal (i.e., they should not be submitted in one combined package).  
352 The sponsor should indicate in the rare pediatric disease designation request whether or not it is  
353 requesting orphan-drug designation or fast track designation at the same time. See Question 10  
354 for how to submit a rare pediatric disease designation request.

355

356 We remind sponsors of the timing for orphan-drug and fast track designation requests:

357

---

<sup>29</sup> Section 529(e)(2).

<sup>30</sup> Section 529(b)(5). FDA may not award any rare pediatric disease priority review vouchers after September 30, 2022, even for applications for drugs granted rare pediatric disease designation by September 30, 2020.

<sup>31</sup> 21 U.S.C. 360bb.

<sup>32</sup> 21 U.S.C. 356.

## *Contains Nonbinding Recommendations*

*Draft – Not for Implementation*

358 *Timing of Requests for Orphan-Drug Designation:* Under section 526, orphan-drug  
359 designation requests must be submitted before the sponsor’s filing of a marketing application  
360 for the drug for the orphan use.<sup>33</sup>

361  
362 *Timing of Requests for Fast Track Designation:* Requests for fast track designation may be  
363 submitted at the time of original submission of the investigational new drug (IND)  
364 application or any time thereafter prior to receiving marketing approval of the NDA or BLA,  
365 although FDA encourages that such requests be submitted no later than the sponsor’s pre-  
366 NDA/BLA meeting because many of the features of fast track designation will no longer be  
367 applicable after that time.<sup>34</sup>

368  
369 If sponsors submit a timely request for rare pediatric disease designation, section 529(d)(3)  
370 directs FDA to make a decision on the request no later than 60 days after submission.<sup>35</sup> The  
371 statute directs FDA to decide whether to designate the drug as a drug for a “rare pediatric  
372 disease” *and* whether to designate the application for the drug as “a rare pediatric disease product  
373 application,”<sup>36</sup> as described in response to Question 11.

374  
375 FDA recognizes that some sponsors may wish to submit a rare pediatric disease designation  
376 request at a different time – for example, if they had already submitted requests for orphan-drug  
377 and/or fast track designation before the enactment of FDASIA, or if for whatever reason they  
378 have no interest in submitting either such request but do want to submit a rare pediatric disease  
379 designation request. FDA is willing to accept designation requests submitted at a different time  
380 than that provided by statute as long as FDA receives the designation request before FDA has  
381 filed the NDA/BLA for the drug for the relevant indication. Although we will aim to respond to  
382 such requests in a timely manner, the 60-day response deadline does not apply. We will not  
383 accept requests for rare pediatric disease designation received after FDA has already filed the  
384 NDA/BLA for the drug for the relevant indication.

385  
386 Whether or not a sponsor receives rare pediatric disease designation for its drug, the sponsor  
387 must include a request for a rare pediatric disease priority review voucher in its original  
388 NDA/BLA submission (either in the initial package or up until the point of NDA/BLA filing) in

---

<sup>33</sup> Section 526(a)(1). For more information on orphan-drug designation, see 21 CFR part 316 and <http://www.fda.gov/ForIndustry/DevelopingProductsforRareDiseasesConditions/HowtoapplyforOrphanProductDesignation/default.htm>.

<sup>34</sup> These features include more frequent interactions with the FDA review team, including meetings to discuss study design and other issues, possible rolling review of portions of the marketing application before receipt of the complete application, and possible priority review if supported by clinical data at the time of BLA or NDA submission. For more information on fast track designation and priority review, see FDA Guidance, Expedited Programs for Serious Conditions—Drugs and Biologics, available at:

<http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm358301.pdf>.

See also

<http://www.fda.gov/forconsumers/byaudience/forpatientadvocates/speedingaccesstoimportantnewtherapies/ucm128291.htm>.

<sup>35</sup> FDA interprets this language, “not later than 60 days after the request is submitted,” to mean that FDA must respond within 60 days after receiving the request.

<sup>36</sup> Section 529(d)(3).

## *Contains Nonbinding Recommendations*

*Draft – Not for Implementation*

389 order to be eligible to receive a voucher.<sup>37</sup> See responses to Questions 14 and 15 for information  
390 on requesting such a voucher.

391

### 392 **Q9. What information should these designation requests contain?**

393

394 Sponsors should include the following information in rare pediatric disease designation requests:

395

396 (1) The name and address of the sponsor and the name of the sponsor’s primary contact  
397 person and/or resident agent including title, address, telephone number, and email  
398 address;

399

400 (2) The non-proprietary and trade name, if any, of the drug, or, if neither is available, the  
401 chemical name or a meaningful descriptive name of the drug;

402

403 (3) The proposed dosage form and route of administration;

404

405 (4) A description of the rare pediatric disease for which the drug is being or will be  
406 investigated; the proposed use of the drug; and the IND number if previously assigned;

407

408 (5) A description of the drug to include (i) the identity of the active moiety, if it is a drug  
409 composed of small molecules, or of the principal molecular structural features, if it is  
410 composed of macromolecules, and (ii) its physical and chemical properties, if these  
411 characteristics can be determined;

412

413 (6) An explanation of the mechanism of action, with supportive data, suggesting that the  
414 drug may be effective in the rare pediatric disease;<sup>38</sup>

415

416 (7) The basis for concluding that the drug is for a “rare disease or condition.” This basis  
417 is established when a sponsor provides the following information, as described in Section  
418 526 of the FD&C Act:<sup>39</sup>

419 (i) Documentation, with appended authoritative references, to demonstrate that (a)  
420 the estimated prevalence of the affected patient population in the U.S. – those  
421 diagnosed with the disease or condition – is below 200,000 at the time of  
422 submission of the request for designation, or (b) if the drug is a vaccine,  
423 diagnostic drug, or preventive drug, the persons to whom the drug will be  
424 administered in the U.S. are fewer than 200,000 per year. Please provide a list of  
425 sources for the information, including dates of the information provided and

---

<sup>37</sup> Section 529(b)(4)(A)(i).

<sup>38</sup> As explained in response to Question 31, FDA expects a lesser level of supportive data for rare pediatric disease designation than for orphan-drug designation because of the many differences between the two programs. In vitro data supporting the mechanism of action of the drug in the disease or in a related disease may suffice for rare pediatric disease designation, whereas that level of data would not generally suffice for orphan-drug designation.

<sup>39</sup> See 21 CFR 316.20.

*Contains Nonbinding Recommendations*

*Draft – Not for Implementation*

426 literature citations (see response to Question 1 for more information on estimating  
427 prevalence); or

428 (ii) For drugs intended for diseases or conditions affecting 200,000 or more  
429 people in the U.S., or for a vaccine, diagnostic drug, or preventive drug that  
430 would be given to 200,000 or more persons in the U.S. per year, a summary of the  
431 sponsor’s basis for believing that the disease or condition occurs so infrequently  
432 that there is no reasonable expectation that the costs of drug development and  
433 marketing will be recovered in future sales of the drug in the U.S. We ask that  
434 sponsors include the same sort of cost and related information as is detailed at 21  
435 CFR 316.21(c).

436 (8) Documentation, with appended authoritative references, to demonstrate that the rare  
437 disease or condition for which the drug is proposed is a “rare pediatric disease” as  
438 defined in section 529(a)(3)(A), meaning that the disease is a serious or life-threatening  
439 disease in which the serious or life-threatening manifestations primarily affect individuals  
440 aged from birth to 18 years (see response to Question 1). The sponsor should include an  
441 analysis of the serious or life-threatening manifestations of the disease and evidence  
442 supporting whether each serious or life-threatening manifestation primarily affects  
443 children or adults. Please provide a list of sources for the information, including dates of  
444 the information provided and literature citations.

445  
446 (9) Where a sponsor requests designation of a drug for only a subset of persons with a  
447 particular disease or condition that otherwise affects 200,000 or more people (“orphan  
448 subset” of non-rare disease or condition), a demonstration that, due to one or more  
449 properties of the drug, the remaining persons with such disease or condition would not be  
450 appropriate candidates for use of the drug (see Question 1 and footnote 13). Such  
451 properties of the drug may include drug toxicity, mechanism of action, or previous  
452 clinical experience with the drug.

453  
454 If a sponsor is submitting a rare pediatric disease designation request at the same time as or  
455 shortly after a request for orphan-drug designation for the drug, it can cross-reference any of the  
456 above information already contained in their orphan-drug designation request.<sup>40</sup> The sponsor  
457 should indicate in the rare pediatric disease designation request whether or not it is requesting  
458 orphan-drug designation or fast track designation at the same time as the request for rare  
459 pediatric disease designation.

460  
461 **Q10. What is the process for submitting rare pediatric disease designation requests?**

462  
463 Sponsors should submit two copies, with at least one hard copy, of the completed, dated, and  
464 signed rare pediatric disease designation requests, with the information specified in response to

---

<sup>40</sup> Cross-referencing of information in previously submitted orphan-drug designation requests may not be appropriate if the information is outdated, for example, if prevalence estimates for the disease have changed in the intervening time between submission of the orphan-drug designation request and submission of the rare pediatric disease designation request.



## *Contains Nonbinding Recommendations*

*Draft – Not for Implementation*

465 Question 9 to the Office of Orphan Products Development, Food and Drug Administration, Bldg.  
466 32, rm. 5295, 10903 New Hampshire Ave., Silver Spring, MD 20993.

467

### **Q11. How will FDA respond to such designation requests?**

468

469  
470 The statute requires that FDA, in responding to rare pediatric disease designation requests,  
471 decide whether to designate the drug as a drug for a “rare pediatric disease” *and* whether to  
472 designate the associated marketing application as a “rare pediatric disease product application.”<sup>41</sup>  
473 The Office of Orphan Products Development (OOPD) and the Office of Pediatric Therapeutics  
474 (OPT) will issue the designation response in consultation with the Center for Drug Evaluation  
475 and Research (CDER) and the Center for Biologics Evaluation and Research (CBER), as  
476 appropriate. This designation response will take one of the following forms:

477

478 *A Deficiency Letter:* FDA will send a deficiency letter within the timeframe specified in  
479 Question 8 if the request lacks the information described in Question 9 or contains inaccurate or  
480 incomplete information. In the deficiency letter, we will ask the sponsor to respond within 60  
481 days or else request an extension of time to respond within that same timeframe; otherwise, FDA  
482 may consider the designation request voluntarily withdrawn.

483

484 *Designating the Drug as a Drug for a “Rare Pediatric Disease” and Either Denying or*  
485 *Conditionally Designating the Application as a “Rare Pediatric Disease Product Application”:*  
486 FDA will designate a drug as a drug for a “rare pediatric disease” within the timeframe specified  
487 in response to Question 8 if the sponsor provides adequate information to demonstrate that the  
488 drug is for a rare pediatric disease (including appropriate prevalence estimates with appended  
489 authoritative references) and an adequate explanation, with supportive data, of the drug’s  
490 mechanism of action suggesting that the drug may be effective in the rare pediatric disease (see  
491 response to Question 9). FDA will evaluate prevalence as of the time of submission of the  
492 designation request. If FDA designates the drug as a drug for a “rare pediatric disease,” these  
493 prevalence estimates generally will not be reevaluated at the time of NDA/BLA submission,<sup>42</sup>  
494 but FDA will evaluate the remaining eligibility criteria to determine whether the NDA/BLA is  
495 eligible for a priority review voucher (see Question 2).

496

497 Even if FDA designates the drug as a drug for a “rare pediatric disease,” FDA cannot  
498 definitively designate any associated marketing application as a “rare pediatric disease product  
499 application” because eligibility cannot be determined unless and until the application is approved  
500 or licensed. This is because eligibility depends on the contents of the application as well as  
501 certain facts at the time of approval or licensure (see Question 2). Short of designating the  
502 application, FDA has two options in responding to the application portion of a designation  
503 request:

504

---

<sup>41</sup> Section 529(d)(3)(A) and (B).

<sup>42</sup> FDA does reserve the right to revisit a decision on prevalence estimates if it becomes apparent that information relevant to that question and available at the time of the submitted request for designation was not provided to FDA or known by FDA at the time of designation decision.

## *Contains Nonbinding Recommendations*

*Draft – Not for Implementation*

505 (1) *to conditionally designate the application* as a “rare pediatric disease product  
506 application” assuming that, at the time of approval or licensure, it will meet all of the  
507 eligibility criteria set forth in section 529(a)(4). The final answer to a conditional  
508 designation of an application will come in the form of a voucher award or non-award at  
509 the time of marketing approval, if the sponsor requests such a voucher in the NDA/BLA.  
510 As described in responses to Questions 14 and 15, even sponsors who receive rare  
511 pediatric disease designation must include a voucher request in their original NDA/BLA  
512 submission if they remain interested in receiving a voucher.<sup>43</sup>

513  
514 (2) *to deny designating the application* if, at the time of submission of the designation  
515 request, it appears the application will fail to meet at least one of the criteria to be a rare  
516 pediatric disease product application (see Question 2). Even sponsors who have been  
517 denied such designation may request a voucher in their NDA/BLA submission if they  
518 believe they are eligible (see responses to Questions 14 and 15).

519  
520 *Neither Designating the Drug as a Drug for a “Rare Pediatric Disease” Nor*  
521 *Designating the Application as a “Rare Pediatric Disease Product Application”*: If FDA  
522 determines that the drug is not in fact a drug for a “rare pediatric disease,” FDA will deny rare  
523 pediatric disease designation of both the drug and the application. Reasons for such denial  
524 include:

- 525 • the drug is not for a “rare disease or condition” under section 526 (e.g., prevalence in  
526 the U.S. is 200,000 or greater), and the drug is not for an “orphan subset” of a non-  
527 rare disease or condition;
- 528 • the drug is not for a disease or condition (or “orphan subset” of a disease or  
529 condition) that “is a serious or life-threatening disease in which the serious or life-  
530 threatening manifestations primarily affect individuals aged from birth to 18 years”;
- 531 • there is insufficient evidence to support the necessary prevalence estimates or to  
532 demonstrate an orphan subset;
- 533 • lack of an adequate explanation, with supportive data, of the drug’s mechanism of  
534 action suggesting that the drug may be effective in the rare pediatric disease;
- 535 • the request contains an untrue statement of material fact, omits material information,  
536 or is otherwise ineligible for designation.

537  
538 Even if a sponsor is denied rare pediatric disease designation, the sponsor can request a rare  
539 pediatric disease priority review voucher at the time of NDA/BLA submission if the sponsor  
540 believes the submission is eligible (see responses to Questions 14 and 15).

541  
542 *Voluntarily Withdrawn Letter*: FDA may consider a designation request voluntarily  
543 withdrawn if the sponsor fails to respond to a deficiency letter, or to request an extension of time  
544 to respond, within 60 days of the deficiency letter date. In the event FDA considers a request  
545 voluntarily withdrawn, FDA will notify the sponsor in writing. As above, such sponsors can still  
546 request a voucher in the NDA/BLA submission if they believe they are eligible.

547

---

<sup>43</sup> Section 529(b)(4)(A)(i).

## *Contains Nonbinding Recommendations*

*Draft – Not for Implementation*

548 *Not Accepted Letter:* As noted in response to Question 8, FDA will not accept requests  
549 for rare pediatric disease designation received after FDA has already filed the NDA/BLA for the  
550 drug for the relevant indication. Such sponsors may still receive a voucher if they requested a  
551 voucher in the NDA/BLA submission and they are otherwise eligible.  
552

553 **Q12. What if a sponsor chooses not to submit a rare pediatric disease designation request**  
554 **before submitting the marketing application?**  
555

556 Sponsors who choose not to submit a rare pediatric disease designation request may nonetheless  
557 receive a priority review voucher if they request such a voucher in their original marketing  
558 application,<sup>44</sup> meet all of the eligibility criteria, and (under the law as applicable at the time of  
559 issuance of this draft guidance) the application is approved by September 30, 2020. The  
560 determination of whether the drug is for a “rare pediatric disease” will occur as described above,  
561 except the prevalence determination will be based on the prevalence at the time of NDA/BLA  
562 submission rather than the prevalence at the time of designation request.  
563

564 We encourage sponsors who are interested in receiving a rare pediatric disease priority review  
565 voucher to notify FDA early of their interest (e.g., no later than a pre-NDA/BLA meeting).  
566 However, notification before submission of the rare pediatric disease product application is not  
567 required. The process for requesting a voucher at the time of NDA/BLA submission is described  
568 in Questions 14 and 15.  
569

### **C. Requesting a Rare Pediatric Disease Priority Review Voucher**

570  
571  
572 **Q13. Do sponsors need to receive rare pediatric disease designation before requesting a**  
573 **priority review voucher?**  
574

575 In general, a sponsor does not need to receive rare pediatric disease designation for its drug in  
576 order to request a priority review voucher. However, under the law as applicable at the time of  
577 issuance of this draft guidance, FDA may not award a voucher after September 30, 2020, unless  
578 the application is for a drug that was designated as a drug for a rare pediatric disease by  
579 September 30, 2020 and the application is approved by September 30, 2022.  
580

581 **Q14. When should sponsors request a rare pediatric disease priority review voucher?**  
582

583 Whether or not sponsors have requested rare pediatric disease designation, sponsors seeking a  
584 rare pediatric priority review voucher must submit a voucher request in the original submission  
585 of the potential rare pediatric disease product application – either in the initial package sent or up  
586 until the point of NDA/BLA filing.<sup>45</sup> This voucher request should be prominently marked, “Rare  
587 Pediatric Disease Priority Review Voucher Request,” and be included or referenced in a cover  
588 letter.  
589

590 **Q15. What information should sponsors include in a priority review voucher request?**

---

<sup>44</sup> Section 529(b)(4)(A)(i).

<sup>45</sup> *Id.*

## *Contains Nonbinding Recommendations*

*Draft – Not for Implementation*

591

592 This request for a voucher should describe how the application meets the eligibility criteria in  
593 section 529(a)(4) of the FD&C Act (See Question 2). The sponsor should address how the  
594 application meets each of the criteria, even if FDA already designated the application as a rare  
595 pediatric disease product application at the designation stage.

596

597 Depending on whether the sponsor has already received rare pediatric disease designation for the  
598 drug, the contents of the voucher request should include the following to support that the drug is  
599 for the prevention or treatment of a rare pediatric disease:

600

### *Sponsors Who Have Received Rare Pediatric Disease Designation for the Drug:*

602 Sponsors who have received rare pediatric disease designation for the drug should include that  
603 designation letter with the voucher request and need not re-analyze prevalence estimates at the  
604 time of NDA/BLA submission.

605

606 *Sponsors Who Have Requested but Not Received Rare Pediatric Disease Designation for*  
607 *the Drug:* Sponsors who have requested but not received rare pediatric disease designation  
608 should include in a voucher request the latest designation correspondence from FDA (i.e., an  
609 acknowledgment letter, deficiency letter, denial letter, or voluntarily withdrawn letter). Note that  
610 under the law as applicable at the time of issuance of this draft guidance, if sponsor does not  
611 have rare pediatric disease designation for their drug by September 30, 2020, FDA may not  
612 award a voucher after September 30, 2020.

613

614 If the designation request has been denied or withdrawn, then the voucher request should include  
615 new prevalence estimates as of the time of NDA/BLA submission; otherwise, the sponsor can  
616 cross-reference the information in its designation request and provide additional information as  
617 necessary. In particular:

618

- 619 • Sponsors who have received only an *acknowledgment letter* in response to a  
620 designation request should cross-reference their designation request (with associated  
621 prevalence estimates).
- 622 • Sponsors who have received a *deficiency letter* should include a response to the  
623 deficiency letter with their voucher requests or else cross-reference a previously  
624 submitted deficiency response.
- 625 • Sponsors who have received *denial letters* should explain how their drug is for a “rare  
626 pediatric disease” despite this denial, based on new information about the drug or the  
627 disease/condition, and include new prevalence estimates as of the time of NDA/BLA  
628 submission (with supporting documentation described in Question 9 items (7)-(8)).
- 629 • Sponsors who have received *voluntarily withdrawn letters* should likewise include  
630 new prevalence estimates as of the time of NDA/BLA submission (with supporting  
631 documentation described in Question 9 items (7)-(8)).

632

633 *Sponsors Who Have Not Requested Rare Pediatric Disease Designation:* Sponsors who  
634 have not requested rare pediatric disease designation should include in a voucher request  
635 prevalence estimates as of the time of NDA/BLA submission, with supporting documentation

## ***Contains Nonbinding Recommendations***

*Draft – Not for Implementation*

636 described in Question 9 items (7)-(8). Note that if a sponsor does not have rare pediatric disease  
637 designation for their drug, FDA may not award a voucher after September 30, 2020.

638

### **D. Using and Transferring a Rare Pediatric Disease Priority Review Voucher**

640

#### **Q16. What is a priority review?**

642

643 The “priority review” awarded by the voucher is the same as the priority review referred to in the  
644 current PDUFA goals letter, which commits FDA to a goal of completing a certain percentage of  
645 priority reviews within the prescribed time frames. For example, in a PDUFA goals letter, FDA  
646 may commit to completing 90 percent of priority reviews within the prescribed time frames.

647 FDA’s current PDUFA goals letter is available on its website.<sup>46</sup> FDA intends to treat any human  
648 drug application for which a PRV is used as if it were any other priority review drug application  
649 under the goals letter.

650

#### **Q17. What is a priority review voucher and when is it awarded?**

652

653 Under section 529(a)(2) of the FD&C Act, a *priority review voucher* is a voucher that FDA  
654 issues to the sponsor of a rare pediatric disease product application at the time of the marketing  
655 application approval. This voucher entitles the holder to designate a single human drug  
656 application submitted under section 505(b)(1) of the FD&C Act<sup>47</sup> or section 351 of the PHS Act  
657 as qualifying for a priority review. Such a subsequent application would not have to meet the  
658 usual requirements for a priority review, but it would have to be submitted after the approval of  
659 the rare pediatric disease product application.

660

#### **Q18. What form will the voucher take?**

662

663 We will include information related to the priority review voucher in the approval letter for the  
664 rare pediatric disease product application. This letter will include a priority review voucher  
665 identification number, which should be referenced when redeeming or transferring the voucher.

666

#### **Q19. How and when can a voucher be used?**

668

669 The application using the priority review voucher must be submitted under section 505(b)(1) of  
670 the FD&C Act<sup>48</sup> or section 351 of the PHS Act and is not limited to drugs for rare pediatric  
671 diseases. The application using the voucher may be for a new indication of the same drug whose  
672 approval led to the award of the voucher. The sponsor redeeming the voucher must notify FDA  
673 of its intent to submit an application with a priority review voucher at least 90 days before  
674 submission of the application and must include the date the sponsor intends to submit the  
675 application (hereinafter “the intended submission date”).<sup>49</sup> This notification should be  
676 prominently marked, “Notification of Intent to Submit an Application with a Rare Pediatric

---

<sup>46</sup> <https://www.fda.gov/downloads/forindustry/userfees/prescriptiondruguserfee/ucm511438.pdf>.

<sup>47</sup> See footnote 9.

<sup>48</sup> See footnote 9.

<sup>49</sup> Section 529(b)(4)(B)(i).

## ***Contains Nonbinding Recommendations***

*Draft – Not for Implementation*

677 Disease Priority Review Voucher.” Upon submitting this notification to FDA, the sponsor is  
678 obligated to pay the priority review user fee described in the response to Question 22.<sup>50</sup>  
679

680 The voucher cannot be used if the application is submitted before the intended submission date.  
681 If a sponsor does not submit the application on the intended submission date, the sponsor should  
682 inform FDA as soon as possible of the new intended submission date. If the sponsor decides not  
683 to use the voucher for the application described in the notification, the sponsor should withdraw  
684 the notification from FDA. The sponsor should submit a new notification informing FDA, at  
685 least 90 days before application submission, of its intent to submit a different human drug  
686 application with a priority review voucher and include the intended submission date.<sup>51</sup>  
687

### **Q20. Will these vouchers be transferable?**

688  
689  
690 Yes. The sponsor of a rare pediatric disease drug receiving a priority review voucher may  
691 transfer (including by sale) the voucher to another sponsor.<sup>52</sup> The voucher may be further  
692 transferred any number of times before the voucher is used, as long as the sponsor making the  
693 transfer has not yet submitted the application.<sup>53</sup>  
694

### **Q21. What is the procedure for voucher transfer?**

695  
696  
697 Each person to whom a voucher is transferred must notify FDA of the change of voucher  
698 ownership within 30 days after the transfer.<sup>54</sup> This notification should be prominently marked,  
699 “Transfer of Rare Pediatric Disease Priority Review Voucher” and submitted to the NDA/BLA.  
700 It should include a letter from the previous owner to the current owner and a letter from the  
701 current owner to the previous owner, each acknowledging the transfer. Any sponsor redeeming a  
702 voucher should include these transfer letters in the application submitted to FDA (in addition to  
703 notifying FDA of the intent to submit an application with a priority review voucher, as described  
704 in response to Question 19). A complete record of transfer must be made available to FDA in  
705 order to redeem a transferred voucher.<sup>55</sup>  
706

### **Q22. What fees apply when using a priority review voucher?**

707  
708  
709 The sponsor of a human drug application that is the subject of a priority review voucher must  
710 pay a priority review user fee in addition to any other required user fee.<sup>56</sup> The amount of the  
711 priority review user fee will be determined each fiscal year and is based on the difference  
712 between the average costs incurred by FDA, in the previous fiscal year, of reviewing a priority  
713 review NDA/BLA and an NDA/BLA that is not subject to priority review.<sup>57</sup> Payment of this

---

<sup>50</sup> *Id.*

<sup>51</sup> *Id.*

<sup>52</sup> Section 529(b)(2).

<sup>53</sup> Section 529(b)(4)(B)(ii).

<sup>54</sup> Section 529(b)(2)(B).

<sup>55</sup> *Id.* See also section 529(b)(4)(B).

<sup>56</sup> Section 529(c)(1).

<sup>57</sup> Section 529(c)(2).

## *Contains Nonbinding Recommendations*

*Draft – Not for Implementation*

714 extra fee, to which the sponsor is legally committed as a result of the notification of its intent to  
715 use the voucher, is not subject to waivers, exemptions, reductions, or refunds.<sup>58</sup>

716

717 FDA will establish the fee amount before the beginning of each fiscal year and will publish the  
718 fee schedule in the *Federal Register*.

719

### **Q23. When do I pay the priority review voucher user fee?**

720

721  
722 The priority review voucher user fee is due upon notifying FDA of the intent to submit an  
723 application with a priority review voucher, as described in the response to Question 19.<sup>59</sup> It is  
724 payable in accordance with procedures established by FDA, which will be described in the  
725 *Federal Register* notice that sets the fees for each fiscal year. The application will be considered  
726 incomplete if the priority review voucher user fee and all other applicable user fees are not paid  
727 in accordance with FDA payment procedures.<sup>60</sup>

728

### **Q24. If I present a voucher to FDA for priority review, am I guaranteed a 6-month review on my drug application?**

729

730

731

732 Although FDA's goal is to take action on the application within 6 months after the 60-day filing  
733 period for an application involving a new molecular entity or within 6 months after the date of  
734 receipt of an application not involving a new molecular entity,<sup>61</sup> this timeframe is not  
735 guaranteed. Note that "take action" in this context means that FDA aims to complete its review  
736 of the filed application and issue an approval or complete response letter within this timeframe; it  
737 does not mean that the application will be approved within this timeframe.

738

## **E. Specific Eligibility Questions**

739

### **Q25. Is eligibility for a priority review voucher affected by whether the sponsor intends to market the rare pediatric disease drug after approval?**

740

741

742

743

744

745

746

747

748

749

750

751

752

753

754

---

<sup>58</sup> Section 529(c)(4)(C).

<sup>59</sup> Section 529(c)(4)(A).

<sup>60</sup> Section 529(c)(4)(B).

<sup>61</sup> See footnote 45.

## *Contains Nonbinding Recommendations*

*Draft – Not for Implementation*

755 been approved in any other application under section 505(b) of the FD&C Act.<sup>62</sup> For example,  
756 an application for a fixed-combination drug that contains a drug substance with a single, new  
757 active moiety may be eligible for a voucher, even if the fixed-combination also contained a drug  
758 substance with a previously approved active moiety.

759

760 **Q27. Are drugs eligible for a priority review voucher if they have been approved and**  
761 **used in other countries but have not been previously approved by FDA?**

762

763 Yes, as long as they meet all the criteria for a rare pediatric disease product application described  
764 in section 529(a)(4) (see section III.A.).

765

766 **Q28. Is a drug that is already approved by FDA for another indication eligible for a**  
767 **priority review voucher for a rare pediatric disease product application?**

768

769 No. As noted, for an application to qualify for a rare pediatric disease priority review voucher, it  
770 must be for a human drug that contains no active ingredient (including any ester or salt of the  
771 active ingredient) that has been previously approved in any other application under section  
772 505(b)(1), 505(b)(2), or 505(j) of the FD&C Act or section 351(a) or 351(k) of the PHS Act.<sup>63</sup>

773

774 **Q29. Would a new pediatric formulation for a drug already approved for adults be**  
775 **eligible for a rare pediatric disease priority review voucher?**

776

777 No. As noted, an application for a drug containing a previously approved active ingredient  
778 (including any ester or salt of the active ingredient) is not eligible to receive a rare pediatric  
779 disease priority review voucher.

780

781 **Q30. Would an application for a rare pediatric disease drug submitted to FDA before**  
782 **enactment of PDUFA of 2012 (under FDASIA) but not yet approved qualify for a**  
783 **voucher?**

784

785 No. The rare pediatric disease product sponsor may not receive a rare pediatric disease priority  
786 review voucher if the application was submitted to FDA prior to October 7, 2012 (90 days after  
787 the date of the enactment of PDUFA of 2012).<sup>64</sup>

788

789

---

<sup>62</sup> See section 529(a)(4)(A)(ii) of the FD&C Act. Because section 529(a)(4)(A)(ii) of the FD&C Act contains the same phrase (“no active ingredient (including any ester or salt of the active ingredient)” that has been previously approved) as is used in sections 505(c)(3)(E)(ii) and (j)(5)(F)(ii) of the FD&C Act, FDA will follow, for drugs approved under the FD&C Act, its guidance on exclusivity for combination drugs under those provisions. See the guidance for industry *New Chemical Entity Exclusivity Determinations for Certain Fixed-Drug Combination Drug Products* (2014). For biological products approved under the PHS Act, FDA will make decisions on eligibility under section 529(a)(4)(A)(ii) of the FD&C Act on a case-by-case basis.

<sup>63</sup> Section 529(a)(A)(ii).

<sup>64</sup> Section 529(b)(3).



## *Contains Nonbinding Recommendations*

*Draft – Not for Implementation*

### 790 **F. Relationship between Rare Pediatric Disease Designation and Orphan-Drug** 791 **Designation**

#### 792 793 **Q31. Will a drug that receives rare pediatric disease designation also qualify for orphan-** 794 **drug designation?**

795  
796 We anticipate that many rare pediatric disease drugs will qualify for designation as orphan drugs  
797 (if such designation is sought) because a “rare pediatric disease” also must be a “rare disease or  
798 condition” as defined in section 526, including those that affect fewer than 200,000 persons in  
799 the U.S.<sup>65</sup> There are instances, however, where a drug may qualify as a drug for a “rare pediatric  
800 disease” but not qualify for orphan-drug designation, or vice versa, as explained below. The  
801 following examples illustrate situations in which a drug might receive rare pediatric disease  
802 designation but not also immediately qualify for orphan drug designation:

- 803
- 804 • Assume that a drug receives “rare pediatric disease” designation but is considered the  
805 “same drug” under the orphan drug regulations as an already approved drug for the same  
806 orphan use. 21 CFR 316.3(b)(14). This drug would not be eligible to receive orphan-  
807 drug designation absent a plausible hypothesis that it may be clinically superior to the  
808 already approved drug. 21 CFR 316.20(a) and (b)(5). *Note:* Even though this drug may  
809 receive “rare pediatric disease” designation, the application for the drug may not qualify  
810 as an “application for a rare pediatric disease product application” – and hence not be  
811 likely to receive a priority review voucher – if it contains a previously approved active  
812 ingredient (including any ester or salt of the active ingredient).  
813
  - 814 • Assume a sponsor plans to develop a drug for a rare pediatric disease but so far has very  
815 little data suggesting that the drug may be effective in that disease (e.g., only in vitro data  
816 supporting the drug’s mechanism of action in a related disease). It is possible that this  
817 level of data may suffice for rare pediatric disease designation but generally it would not  
818 suffice for orphan-drug designation. This is because, to qualify for orphan-drug  
819 designation, an applicant must supply sufficient information to establish a medically  
820 plausible basis for expecting the drug to be effective in the prevention, diagnosis, or  
821 treatment of the rare disease or condition.<sup>66</sup> The sponsor may eventually obtain orphan  
822 designation for the drug after developing or obtaining more supportive data for use of the  
823 drug for the rare disease or condition, including in vivo and/or clinical data in the rare  
824 disease or condition.

825  
826 If a drug receives orphan-drug designation, it may be eligible for orphan-drug exclusivity, tax  
827 credits for qualified clinical testing, orphan product grant funding, as well as fee exemptions  
828 under section 736 of the FD&C Act. For information regarding these orphan drug incentives,  
829 please contact the OOPD at [orphan@fda.hhs.gov](mailto:orphan@fda.hhs.gov) or 301-796-8660. For information regarding  
830 user fee exemptions, please contact the User Fee staff in CDER’s Office of Management at 301-  
831 796-7900.  
832

---

<sup>65</sup> Section 529(a)(3)(B). *See also* section 526.

<sup>66</sup> See 21 CFR 316.25(a)(2).

## *Contains Nonbinding Recommendations*

*Draft – Not for Implementation*

### 833 **G. Agency’s Responsibilities and Roles**

834

835 **Q32. What are the Agency’s responsibilities if it issues a priority review voucher under**  
836 **section 529 or if it approves a drug application for which the sponsor used such a**  
837 **voucher?**

838

839 As per section 529(f)(1), FDA will publish a notice in the *Federal Register* and on its website<sup>67</sup>  
840 within 30 days after issuing a priority review voucher under section 529 and within 30 days after  
841 approving a drug application for which the sponsor used such a voucher.

842

843 **Q33. What are the different roles played by CDER, CBER, OOPD, and OPT?**

844

#### 845 CDER and CBER

846

847 The applicable review divisions and offices within CDER and CBER have the responsibility for  
848 premarket review of the rare pediatric disease product applications and for determining whether  
849 an application meets the eligibility criteria for receiving a priority review voucher. CDER and  
850 CBER will consult with OOPD and OPT as to whether a disease/condition is a “rare pediatric  
851 disease” as defined in section 529(a)(3).

852

#### 853 OOPD and OPT

854

855 OOPD and OPT, both within the Office of the Commissioner, are distinct from CDER and  
856 CBER and are responsible for determining whether a drug (including a biological product)  
857 qualifies for designation as a drug for a “rare pediatric disease” as defined in section 529(a)(3), if  
858 such designation is requested.

859

860 Specifically, OOPD determines if the drug is for a rare disease or condition within the meaning  
861 of Section 526. OPT determines if the drug is for a disease that is a serious or life-threatening  
862 disease in which the serious or life-threatening manifestations primarily affect individuals aged  
863 from birth to 18 years. OOPD and OPT will consult with CDER and CBER as appropriate.

864

865 OOPD is also responsible for granting orphan-drug designation to drugs (including biological  
866 products) under section 526 and 21 CFR part 316. As noted in Question 31, whether a drug  
867 receives orphan-drug designation is a different question from whether it receives designation as a  
868 drug for a “rare pediatric disease.” Questions about the orphan designation program should be  
869 directed to OOPD.

870

871 In the event a sponsor does not request rare pediatric disease designation but does request a rare  
872 pediatric disease priority review voucher at the time of NDA/BLA submission, the review  
873 division or office within CDER and CBER will consult with OOPD and OPT, as appropriate, as  
874 to whether the disease/condition is a “rare pediatric disease” as defined in section 529(a)(3).

---

<sup>67</sup> <http://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/ucm375479.htm>

*Contains Nonbinding Recommendations*

*Draft – Not for Implementation*

875

876 **Q34. Whom should I contact if I have questions about a rare pediatric disease product**  
877 **application?**

878

879 Sponsors with questions not addressed in this guidance should contact OOPD for questions  
880 related to designation as a rare disease, OPT for questions related to designation as a rare  
881 pediatric disease, and the appropriate review division or office within CDER or CBER for  
882 questions related to rare pediatric disease product applications. CDER and CBER encourage  
883 early interaction with potential sponsors on these issues (e.g., in a pre-IND meeting or early in  
884 the clinical development program).